Trial
NCT04877457
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
Genentech, Inc.
Condition
Radiologically Isolated Syndrome
Intervention
Ocrelizumab
Why stopped
Slow enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-09